ArticleFrontiers in oncology2023

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF

Gudrun Piringer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.